Search research articles
Contact Us
Filters
Showing results (181-190 of 316) with videos related to
Page
of 32
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
K K Matthay, K DeSantes, B Hasegawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study
C A Perez, K K Matthay, J B Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results
K K Matthay, M C O'Leary, N K Ramsay, et al.
Pediatric Blood & Cancer
|
January 31, 2006
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A Messina, Su-Chun Cheng, Benjamin L Franc, et al.
Pediatric Blood & Cancer
|
January 6, 2010
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group
Pamela Bensimhon, Judith G Villablanca, Leonard S Sender, et al.
Cancer Letters
|
July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
Wendy B London, Luca Boni, Thorsten Simon, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2000
Intraoperative radiation therapy for high-risk pediatric neuroblastoma
D A Haas-Kogan, B M Fisch, W M Wara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
Julie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study
Wendy B London, Christopher N Frantz, Laura A Campbell, et al.
Anticancer Research
|
March 14, 2013
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma
Sabine Mueller, Samhita Bhargava, Annette M Molinaro, et al.
Page
of 32
Search research articles
Search
Showing results (181-190 of 316) with videos related to
Sort By:
Page
of 32
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 1998
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma
K K Matthay, K DeSantes, B Hasegawa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study
C A Perez, K K Matthay, J B Atkinson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1995
Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results
K K Matthay, M C O'Leary, N K Ramsay, et al.
Pediatric Blood & Cancer
|
January 31, 2006
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma
Julia A Messina, Su-Chun Cheng, Benjamin L Franc, et al.
Pediatric Blood & Cancer
|
January 6, 2010
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group
Pamela Bensimhon, Judith G Villablanca, Leonard S Sender, et al.
Cancer Letters
|
July 19, 2005
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
Wendy B London, Luca Boni, Thorsten Simon, et al.
International Journal of Radiation Oncology, Biology, Physics
|
June 23, 2000
Intraoperative radiation therapy for high-risk pediatric neuroblastoma
D A Haas-Kogan, B M Fisch, W M Wara, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 20, 2011
Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study
Julie R Park, Jeffrey R Scott, Clinton F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 28, 2010
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study
Wendy B London, Christopher N Frantz, Laura A Campbell, et al.
Anticancer Research
|
March 14, 2013
Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma
Sabine Mueller, Samhita Bhargava, Annette M Molinaro, et al.
Page
of 32